GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (STU:2RH) » Definitions » EPS (Diluted)

Redhill Biopharma (STU:2RH) EPS (Diluted) : €471.46 (TTM As of Jun. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Redhill Biopharma EPS (Diluted)?

Redhill Biopharma's Earnings per Share (Diluted) for the three months ended in Jun. 2024 was €0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €471.46.

Redhill Biopharma's EPS (Basic) for the three months ended in Jun. 2024 was €0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was €471.46.

Redhill Biopharma's EPS without NRI for the three months ended in Jun. 2024 was €0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was €471.46.

During the past 3 years, the average EPS without NRIGrowth Rate was 72.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 40.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 15.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Redhill Biopharma's highest 3-Year average EPS without NRI Growth Rate was 72.10% per year. The lowest was -51.40% per year. And the median was 0.90% per year.


Redhill Biopharma EPS (Diluted) Historical Data

The historical data trend for Redhill Biopharma's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma EPS (Diluted) Chart

Redhill Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,260.00 -1,726.20 -1,858.50 -1,132.80 91.70

Redhill Biopharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23 Jun24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 467.00 4.46 - -

Competitive Comparison of Redhill Biopharma's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redhill Biopharma's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's PE Ratio falls into.



Redhill Biopharma EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Redhill Biopharma's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(21.931-0)/0.259
=84.68

Redhill Biopharma's Diluted EPS for the quarter that ended in Jun. 2024 is calculated as

Diluted EPS (Q: Jun. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(0-0)/1.176
=0.00

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €471.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Redhill Biopharma  (STU:2RH) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Redhill Biopharma EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Redhill Biopharma Business Description

Traded in Other Exchanges
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

Redhill Biopharma Headlines

No Headlines